142 related articles for article (PubMed ID: 16462182)
1. Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going.
Rosell R; Cuello M; Cecere F; Santarpia M; Reguart N; Felip E; Taron M
Curr Opin Oncol; 2006 Mar; 18(2):135-43. PubMed ID: 16462182
[TBL] [Abstract][Full Text] [Related]
2. The place of targeted therapies in the management of non-small cell bronchial carcinoma. Molecular markers as predictors of tumor response and survival in lung cancer.
Rosell R; Moran T; Fernanda Salazar M; Mendez P; De Aguirre I; Ramirez JL; Isla D; Cobo M; Camps C; Lopez-Vivanco G; Alberola V; Taron M
Rev Mal Respir; 2006 Nov; 23(5 Pt 3):16S131-16S136. PubMed ID: 17268350
[TBL] [Abstract][Full Text] [Related]
3. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
Vilmar A; Sørensen JB
Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
[TBL] [Abstract][Full Text] [Related]
4. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.
Cobo M; Isla D; Massuti B; Montes A; Sanchez JM; Provencio M; Viñolas N; Paz-Ares L; Lopez-Vivanco G; Muñoz MA; Felip E; Alberola V; Camps C; Domine M; Sanchez JJ; Sanchez-Ronco M; Danenberg K; Taron M; Gandara D; Rosell R
J Clin Oncol; 2007 Jul; 25(19):2747-54. PubMed ID: 17602080
[TBL] [Abstract][Full Text] [Related]
5. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
Olaussen KA; Mountzios G; Soria JC
Curr Opin Pulm Med; 2007 Jul; 13(4):284-9. PubMed ID: 17534174
[TBL] [Abstract][Full Text] [Related]
6. Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response.
Felip E; Rosell R
Expert Rev Mol Diagn; 2007 May; 7(3):261-8. PubMed ID: 17489733
[TBL] [Abstract][Full Text] [Related]
7. ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer.
Lee KH; Min HS; Han SW; Oh DY; Lee SH; Kim DW; Im SA; Chung DH; Kim YT; Kim TY; Heo DS; Bang YJ; Sung SW; Kim JH
Lung Cancer; 2008 Jun; 60(3):401-7. PubMed ID: 18036700
[TBL] [Abstract][Full Text] [Related]
8. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
Zhou W; Gurubhagavatula S; Liu G; Park S; Neuberg DS; Wain JC; Lynch TJ; Su L; Christiani DC
Clin Cancer Res; 2004 Aug; 10(15):4939-43. PubMed ID: 15297394
[TBL] [Abstract][Full Text] [Related]
9. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer.
Simon G; Sharma A; Li X; Hazelton T; Walsh F; Williams C; Chiappori A; Haura E; Tanvetyanon T; Antonia S; Cantor A; Bepler G
J Clin Oncol; 2007 Jul; 25(19):2741-6. PubMed ID: 17602079
[TBL] [Abstract][Full Text] [Related]
10. Synchronous alterations of Wnt and epidermal growth factor receptor signaling pathways through aberrant methylation and mutation in non small cell lung cancer.
Suzuki M; Shigematsu H; Nakajima T; Kubo R; Motohashi S; Sekine Y; Shibuya K; Iizasa T; Hiroshima K; Nakatani Y; Gazdar AF; Fujisawa T
Clin Cancer Res; 2007 Oct; 13(20):6087-92. PubMed ID: 17947472
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z
Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
[TBL] [Abstract][Full Text] [Related]
12. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
John T; Liu G; Tsao MS
Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
[TBL] [Abstract][Full Text] [Related]
13. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
[TBL] [Abstract][Full Text] [Related]
14. Characterization of functional excision repair cross-complementation group 1 variants and their association with lung cancer risk and prognosis.
Yu D; Zhang X; Liu J; Yuan P; Tan W; Guo Y; Sun T; Zhao D; Yang M; Liu J; Xu B; Lin D
Clin Cancer Res; 2008 May; 14(9):2878-86. PubMed ID: 18451256
[TBL] [Abstract][Full Text] [Related]
15. Excision repair cross complementation group 1 polymorphisms predict overall survival after platinum-based chemotherapy for completely resected non-small-cell lung cancer.
Okuda K; Sasaki H; Hikosaka Y; Kawano O; Yukiue H; Yano M; Fujii Y
J Surg Res; 2011 Jun; 168(2):206-12. PubMed ID: 20070981
[TBL] [Abstract][Full Text] [Related]
16. Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer.
Okuda K; Sasaki H; Dumontet C; Kawano O; Yukiue H; Yokoyama T; Yano M; Fujii Y
Lung Cancer; 2008 Oct; 62(1):105-12. PubMed ID: 18395930
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor mutations in lung cancer.
Sharma SV; Bell DW; Settleman J; Haber DA
Nat Rev Cancer; 2007 Mar; 7(3):169-81. PubMed ID: 17318210
[TBL] [Abstract][Full Text] [Related]
18. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients.
Suk R; Gurubhagavatula S; Park S; Zhou W; Su L; Lynch TJ; Wain JC; Neuberg D; Liu G; Christiani DC
Clin Cancer Res; 2005 Feb; 11(4):1534-8. PubMed ID: 15746057
[TBL] [Abstract][Full Text] [Related]
19. Molecular predictors of chemotherapy response in non-small-cell lung cancer.
Gray J; Simon G; Bepler G
Expert Rev Anticancer Ther; 2007 Apr; 7(4):545-9. PubMed ID: 17428174
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.
Eberhard DA; Giaccone G; Johnson BE;
J Clin Oncol; 2008 Feb; 26(6):983-94. PubMed ID: 18281673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]